Načítá se...
PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers
The proprotein convertase subtilisin/kexin type 9 inhibitors or monoclonal antibodies likely represent the greatest advance in lipid management in 30 years. In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high‐risk patients with familial hypercholesterolemia (...
Uloženo v:
| Vydáno v: | Clin Cardiol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Periodicals, Inc.
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412679/ https://ncbi.nlm.nih.gov/pubmed/28328015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22713 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|